Description
Paxlovid (nirmatrelvir/ritonavir) tablets
Today, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization (EUA) by the United States Food and Drug Administration (FDA) to treat COVID‑19. It was approved in the United Kingdom later that month, and in the European Union and Canada in January 2022. In May 2023, it was approved in the US to treat mild-to-moderate COVID‑19 in people over 12 years who are at high risk for progression to severe COVID‑19, including hospitalization or death.The FDA considers the combination to be a first-in-class medication.
Get Access to Paxlovid (nirmatrelvir/ritonavir) tablets In India
Medvitaz Pharma is equipped to facilitate the distribution of Paxlovid (nirmatrelvir/ritonavir) tablets (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “Paxlovid (nirmatrelvir/ritonavir) tablets” or the generic version “nirmatrelvir/ritonavir tablets” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.